CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 121 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,829,000 | -16.6% | 279,218 | -15.3% | 0.04% | -44.6% |
| Q3 2020 | $2,192,000 | -26.5% | 329,556 | -8.0% | 0.07% | -31.5% |
| Q2 2020 | $2,983,000 | +46.4% | 358,122 | +34.8% | 0.11% | -1.8% |
| Q1 2020 | $2,038,000 | +59.5% | 265,673 | +72.7% | 0.11% | +86.4% |
| Q4 2019 | $1,278,000 | +12.9% | 153,818 | +0.3% | 0.06% | -4.8% |
| Q3 2019 | $1,132,000 | -31.5% | 153,397 | +4.2% | 0.06% | -24.4% |
| Q2 2019 | $1,652,000 | -1.7% | 147,223 | -5.9% | 0.08% | -8.9% |
| Q1 2019 | $1,681,000 | -31.9% | 156,391 | -4.4% | 0.09% | -48.6% |
| Q4 2018 | $2,470,000 | -20.1% | 163,547 | -2.1% | 0.18% | +4.2% |
| Q3 2018 | $3,091,000 | -16.8% | 167,088 | +2.8% | 0.17% | -25.0% |
| Q2 2018 | $3,715,000 | -19.7% | 162,504 | -0.1% | 0.22% | -32.9% |
| Q1 2018 | $4,626,000 | +140.4% | 162,592 | +78.4% | 0.33% | +121.2% |
| Q4 2017 | $1,924,000 | – | 91,144 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |